patent
6-diazo-5-oxo-l-norleucine prodrugs
2024
The present invention relates to 6-diazo-5-oxo-L-norleucine prodrugs having reduced toxicity and increased tumor specificity and to their therapeutic use for treating cancer.
Type
patent
EPO Family ID
84329966
Note
Alternative title(s) : (fr) Promédicaments de 6-diazo-5-oxo-l-norleucine
TTO classification
TTO:6.2357
EPFL units
| Identifier | Country code | Kind code | Date issued |
WO2024094526 | WO | A1 | 2024-05-10 |
Available on Infoscience
June 3, 2024
Use this identifier to reference this record